YC-1: Dual Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Hypoxia and Cancer Biology

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol enables simultaneous activation of soluble guanylyl cyclase (sGC) and inhibition of hypoxia-inducible factor-1α (HIF-1α), impacting both cGMP and hypoxia signaling pathways in vitro and in vivo [APExBIO]. The compound exhibits a defined IC50 of 1.2 µM for blocking HIF-1 transcriptional activity under hypoxic conditions, with effects confirmed across diverse tumor models (Zhou et al., 2026). YC-1 reduces angiogenesis and tumor growth by suppressing HIF-1α–dependent gene expression. It is soluble at ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol, but insoluble in water, supporting flexible experimental design. APExBIO’s B7641 formulation is supplied at ≥98% purity as crystalline solid for research use only.

Biological Rationale

Oxygen homeostasis is central to cellular metabolism and survival. Hypoxia-inducible factor-1α (HIF-1α) is a master regulator of gene expression under low-oxygen conditions, directing tumor adaptation, angiogenesis, and resistance to therapy (Zhou et al., 2026). Aberrant HIF-1α activity is implicated in cancer, cardiovascular, and cerebrovascular disease. YC-1 targets this axis by inhibiting HIF-1α expression and activity at the post-transcriptional level, disrupting the hypoxia signaling cascade. In parallel, YC-1 activates sGC, enhancing cyclic GMP (cGMP) levels, which modulate vasodilation, platelet aggregation, and vascular tone [Related article]. This dual mechanism addresses two major pathways involved in tumor progression and vascular pathophysiology. While previous summaries focus on single-pathway modulation, this article clarifies how YC-1 coordinates cGMP and hypoxia pathways to provide a comprehensive research tool.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 exerts its anticancer and vascular effects via two principal mechanisms:

• HIF-1α Inhibition: YC-1 blocks HIF-1α protein accumulation under hypoxia, predominantly via post-transcriptional repression, leading to decreased expression of HIF-1–regulated genes (e.g., VEGF, GLUT1).
• sGC Activation: YC-1 allosterically activates soluble guanylyl cyclase in the absence or presence of nitric oxide (NO), boosting intracellular cGMP. This modulates vasodilation, inhibits platelet aggregation, and reduces vascular contraction.

Unlike conventional HIF-1α inhibitors, YC-1 also intersects with the oxygen-sensing pathway, affecting both canonical (PINK1/parkin) and non-canonical (HIF-1α/BNIP3L) mitophagy axes in models of ischemia-reperfusion injury (Zhou et al., 2026). This distinguishes YC-1 from single-target agents, as detailed in recent reviews [see comparison].

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC50 of 1.2 µM in cell-based assays (DMSO, 37°C, pH 7.4) [APExBIO].
• In vivo, YC-1 treatment yields smaller, less vascularized tumors and reduces expression of HIF-1α and its downstream targets (e.g., VEGF) in xenograft models (Zhou et al., 2026).
• YC-1 activates sGC, resulting in increased cGMP and inhibition of platelet aggregation in vitro; effective concentrations ≥1 µM (buffered saline, 22°C) [internal article].
• YC-1 is soluble at ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol, but insoluble in water; purity ≥98% by HPLC [APExBIO].
• Pharmacological inhibition of HIF-1α (as by YC-1) abolishes mitochondrial protection and mitophagy induction in models of cerebral ischemia–reperfusion injury (see Table 1).

Applications, Limits & Misconceptions

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is validated for:

• Dissecting hypoxia signaling and HIF-1α–dependent gene networks in cancer, vascular, and neuronal studies.
• Modulation of tumor angiogenesis and evaluation of anti-angiogenic strategies.
• Investigating cGMP signaling, vasodilation, and platelet function in cardiovascular research.
• Modeling oxygen-sensing pathway interactions in apoptosis and mitochondrial quality control.

For advanced strategies, see "Integrating Hypoxia and cGMP Signaling Modulation", which this article updates with new mechanistic and benchmarking data.

Common Pitfalls or Misconceptions

• YC-1 is not water-soluble; improper vehicle selection may cause precipitation or dosing errors.
• YC-1 is intended for research use only and is not for diagnostic or medical purposes.
• Long-term storage of YC-1 solutions is not recommended; prepare fresh aliquots before use.
• YC-1 is not selective for HIF-2α; effects are primarily via HIF-1α.
• sGC activation by YC-1 may not fully substitute for NO donors in all vascular models.

Workflow Integration & Parameters

YC-1 (APExBIO B7641) is supplied as a crystalline solid with a molecular weight of 304.34. For optimal use:

• Dissolve in DMSO (≥30.4 mg/mL) or ethanol (≥16.2 mg/mL) for stock solutions; avoid water.
• Store powder at room temperature, protected from light and moisture; use solutions promptly.
• Typical in vitro working concentrations: 0.5–10 µM, depending on cell type and assay.
• For in vivo work, refer to published protocols and titrate according to model parameters.
• Confirm purity by HPLC if required for regulatory documentation.

For stepwise protocols and troubleshooting, see this detailed workflow guide, to which this article adds specific solubility and benchmarking clarifications.

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a well-characterized, dual-function reagent for hypoxia signaling, cancer biology, and vascular modulation. Its reproducible inhibition of HIF-1α and activation of sGC make it a foundational tool for dissecting tumor adaptation and oxygen-sensing mechanisms. The B7641 kit from APExBIO provides high-purity, reliable YC-1 for advanced research. Future directions include combinatorial use with H2S modulators and expanded application in mitochondrial quality control, as highlighted in recent mechanistic studies (Zhou et al., 2026). For comprehensive protocols and advanced troubleshooting, refer to the linked internal resources, which this article extends with updated quantitative standards and practical handling notes.